Comparison of three antipsychotics in the emergency psychiatric setting

Human Psychopharmacology

Volumn 18, Issue 6, 2003, Pages 447-452

  Raja, Michele ^a   Azzoni, Antonella ^a  

^a SPIRITO SANTO HOSPITAL   (Italy)

Author keywords

Emergency psychiatry; Olanzapine; Psychosis; Quetiapine; Risperidone

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLOZAPINE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; AKATHISIA; AKINESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DEVELOPMENTAL DISORDER; DRUG EFFICACY; EMERGENCY HEALTH SERVICE; FEMALE; HUMAN; MALE; MENTAL DEFICIENCY; MOOD DISORDER; MUSCLE RIGIDITY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREMOR;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; EMERGENCY SERVICES, PSYCHIATRIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SAMPLING STUDIES; TREATMENT OUTCOME;

EID: 0042926571     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.509     Document Type: Article

References (12)

1. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. 1997. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233-246.
2. Borison RL, Arvanitis LA, Miller BG, and the US Seroquel Study Group. 1996. ICI 204.636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16: 158-169.
3. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. 2000. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 15: 121-131.
4. Essock SM, Frisman LK, Covell NH. 2002. The economics of the treatment of schizophrenia. In Neuropsychopharmacology. The Fifth Generation of Progress, Davis KL, Charney D, Coyle JT, Nemeroff C (eds). Lippincott Williams & Wilkins: Philadelphia; 809-818.
5. Janicak PG, Davis JM, Preskorn SH, Ayd FJ. 2001. Principles and Practice of Psychopharmacotherapy, 3rd edn. Lippincot Williams & Wilkins: Philadelphia; 177-178.
6. Kane JM. 2002. Issues in clinical trial designs. In Neuropsychopharmacology. The Fifth Generation of Progress, Davis KL, Charney D, Coyle JT, Nemeroff C (eds). Lippincott Williams & Wilkins: Philadelphia; 537-546.
7. Miyamoto S, Duncam GE, Goff DC, Lieberman JA. 2002. Therapeutics of schizophrenia. In Neuropsychopharmacology. The Fifth Generation of Progress, Davis KL, Charney D, Coyle JT, Nemeroff C (eds). Lippincott Williams & Wilkins: Philadelphia; 775-807.
8. Morrison EF. 1992. A hierarchy of aggressive and violent behaviors among psychiatric inpatients. Hosp Comm Psychiatry 43: 505-506.
9. Mullen J, Jibson MD, Sweitzer D. 2001. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 23: 1839-1854.
10. Peuskens J, Link CG. 1997. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 96: 265-273.
11. 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine and quetiapine. Am J Psychiatry 156: 876-884.
12. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, and the Seroquel Study Group. 1997. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 54: 549-557.